Researchers evaluated the popular diabetes medication, semaglutide, to determine whether it causes or worsens diabetic retinopathy in patients using the medication. Their findings were presented at AAO 2023...
Researchers compared the effects of once-weekly semaglutide (2.4 mg) with a placebo during a 52-week period in patients with HFpEF and a BMI of 30 or higher.
As neurocognitive decline occurs in the majority of patients with breast cancer, researchers conducted a blind randomized trial to determine if aerobic exercise was an effective intervention for reducing...
The American Gastroenterological Association published a list of recommendations and medications for treating and preventing overweight and obesity in adult patients.